SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549
------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 2, 2004
Eyetech Pharmaceuticals, Inc.
- -------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-50516 13-4104684
- ---------------------------- ------------- -------------------
(State or Other Jurisdiction (Commission (I.R.S. Employer
of Incorporation) File Numbers) Identification No.)
3 Times Square, 12th Floor
New York, NY 10036
- ---------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (212) 824-3100
- -------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
ITEM 5. OTHER EVENTS
On June 2, 2004, Eyetech Pharmaceuticals, Inc. announced the closing of a
secondary offering of selling stockholders. The full text of the press release
issued in connection with the announcement is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: June 3, 2004 EYETECH PHARMACEUTICALS, INC.
By: /s/ Glenn P. Sblendorio
----------------------------------
Name: Glenn P. Sblendorio
Title: Senior Vice President, Finance and
Chief Financial Officer
EXHIBIT INDEX
Exhibit No. Description
- ----------- -----------
99.1 Press release dated June 2, 2004 announcing the closing of a
secondary offering of selling stockholders.